



NEWS RELEASE

FOR IMMEDIATE RELEASE

Incubate bio BV

March 27, 2023

QV Bioelectronics and Incubate bio enter a Strategic Collaboration to Accelerate the Treatment of Glioblastoma

QV Bioelectronics will adopt the ALaSCA software platform as an integral part of its preclinical R&D workflow, enabling the identification and *in silico* simulation of key drivers in complex biological processes.

[Manchester, March 27, 2023]. QV Bioelectronics and Incubate bio announced today that the companies have entered into a strategic partnership that will enable QV Bioelectronics to optimize its capital efficiency for experiments and to maximize its experimental throughput during its preclinical R&D phases.

“Understanding where to spend our experiment dollars is critical to our success,” said Dr Chris Bullock, CEO, QV Bioelectronics. “To achieve this, we require cost-efficient computational approaches to decipher what is happening in the molecular pathways and to even simulate ‘what-if’ scenarios for our scientists. It is a pleasure to partner with Incubate bio to get access to the ALaSCA platform and to integrate into our R&D workflow. Early results have already been very useful to our scientific understanding.”

“QV Bioelectronics has a powerful vision to treat brain diseases using a revolutionary medical implant. We are honored to be part of that journey, and to help accelerate improved care for life threatening diseases such as brain tumours” said Dr Raminderpal Singh, CEO, Incubate bio.

About Incubate bio BV

Incubate bio is revolutionizing how R&D scientists explore and simulate effects during preclinical phases. Incubate bio's platform, ALaSCA (patent pending), uses formal causal methods to untangle the pivots and redundancies within biological pathways - thereby enabling the identification of the optimal nodes for drug and other treatment interventions, and improving the efficiency of targeting for any phenotypic (disease) process. To learn more about ALaSCA and a Type 1 Diabetes case study:

<https://www.biorxiv.org/content/10.1101/2023.03.16.532913v1>

For more about Incubate bio:

<https://www.incubate.bio/>

About QV bioelectronics Ltd

QV Bioelectronics are striving to deliver longer, better quality lives for brain tumor patients. Their implanted electric field therapy, GRACE, aims to address the unmet clinical of glioblastoma (GBM), the most common primary brain tumor. QV Bioelectronics have global aspirations for their treatment, with the ambition of integrating the GRACE implant into the international standard for the treatment of GBM patients. Their therapy aims to change the paradigm of GBM treatment, with the ambition of significantly extending life expectancy without impacting patient quality of life, so patients can focus on what matters to them.

For more about QV Bioelectronics:

<https://www.qvbio.co.uk/>

Media Contact:

Raminderpal Singh

CEO

raminderpal@incubate.bio

+44 7719 622303

<https://www.incubate.bio/>